WAVE Life Sciences (WAVE Life Sciences) Interest Expense : $0.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is WAVE Life Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. WAVE Life Sciences's interest expense for the three months ended in Dec. 2023 was $ 0.0 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.0 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. WAVE Life Sciences's Operating Income for the three months ended in Dec. 2023 was $ -18.7 Mil. WAVE Life Sciences's Interest Expense for the three months ended in Dec. 2023 was $ 0.0 Mil. GuruFocus does not calculate WAVE Life Sciences's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

WAVE Life Sciences Interest Expense Historical Data

The historical data trend for WAVE Life Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WAVE Life Sciences Interest Expense Chart

WAVE Life Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.02

WAVE Life Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

WAVE Life Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

WAVE Life Sciences (NAS:WVE) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

WAVE Life Sciences's Interest Expense for the three months ended in Dec. 2023 was $0.0 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-18.7 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $25.4 Mil.

WAVE Life Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

GuruFocus does not calculate WAVE Life Sciences's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. WAVE Life Sciences Ltd has enough cash to cover all of its debt. Its financial situation is stable.

WAVE Life Sciences (WAVE Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WAVE Life Sciences Ltd (NAS:WVE) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

1U5:Germany

Address

Marina One East Tower, 7 Straits View No. 12-00, Singapore, SGP, 018936

Website

https://www.wavelifesciences.com

WAVE Life Sciences Ltd is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

Executives

Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Kyle Moran	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chris Francis	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Chandra Vargeese	officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Paul Bolno	director, officer: See Remarks	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Plc Glaxosmithkline	10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Michael A. Panzara	officer: Franchise Lead, Neurology	733 CONCORD AVENUE, CAMBRIDGE MA 02138
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Aik Na Tan	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
David G Gaiero	officer: Interim CFO	733 CONCORD AVENUE, C/O WAVE LIFE SCIENCES USA, INC., CAMBRIDGE MA 02138
Gregory L. Verdine	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE, CAMBRIDGE MA 02138
Heidi L Wagner	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Amy Pott	director	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Mark Corrigan	director